Grail's Cancer Blood Test Faces High-Stakes FDA Review

How FDA backing could advance multi-cancer blood tests despite Hong Kong doubts

Doctors say more data is needed despite growing interest in detecting multiple cancers from a single blood sample.

One blood test could screen you for 50 cancers. Here’s why it’s controversial.

A Food and Drug Administration committee backed a cancer blood test called Galleri but was split on how well it works. The test is awaiting a final decision by the FDA.

FDA Panel Recommends Approval Of GRAIL's Galleri Multi-Cancer Early Detection Test

GRAIL Inc.'s (GRAL) Galleri multi-cancer early detection test has received a favorable vote from the FDA panel, making it one step closer to approval. The FDA's final decision on Galleri is expected in the coming months. The U. S. regulator usually follows the recommendations of its panels, although it is not mandatory to do so.

GRAIL's Galleri test wins endorsement from FDA panel (NASDAQ:GRAL)

A panel of US FDA advisors voted that there is reasonable evidence that GRAIL’s (GRAL) multi-cancer early detection blood test Galleri is effective. The vote wa

FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection Test

SUNNYVALE, Calif., Sept. 23, 2026 /PRNewswire/ -- GRAIL, Inc., a healthcare company whose mission is to detect cancer early when it can be cured, today announced a favorable vote from the Molecular and Clinical Genetics Devices Panel of the Medical…

This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval

Grail’s Galleri test looks for 50 cancers from a blood draw, but a major study failed to prove it could detect later-stage cancers.